Buckingham says Watson Pharmaceuticals (WPI -1.3%) remains a Top Pick , given its attractive...

|By:, SA News Editor

Buckingham says Watson Pharmaceuticals (WPI -1.3%) remains a Top Pick , given its attractive growth profile, Actavis acquisition benefits and continued settlement discussions with Endo (ENDP -0.8%). The firm reiterates its Buy rating with a $100 price target.